Autonomix Medical Inc Stock Price, News & Analysis

Autonomix (NASDAQ: AMIX) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,369,852 on October 9, 2025 for "Controlled and Precise Treatment of Cardiac Tissues."

The '852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver therapy with closed-loop feedback for precision neuromodulation, denervation, and ablation of cardiac tissues. The filing is described as adding to a global IP portfolio of over 120 issued and pending patent applications and is positioned to address indications including arrhythmias, refractory angina, heart failure, hypertension, and plaque/inflammation modulation.

Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses two key updates: the company's recent longer-term post hoc analysis from its first-in-human proof-of-concept study (PoC 1) and progress towards U.S. clinical trials scheduled to begin in 2026.

Autonomix Medical (NASDAQ: AMIX) has initiated a crucial Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System, targeting pancreatic cancer pain treatment. The study, conducted at CBSET research institute, represents a significant step toward FDA regulatory approvals.

The company remains on track to submit its Investigational Device Exemption (IDE) and, pending approval, begin U.S. clinical trials in 2026 to support a De Novo FDA application. CEO Brad Hauser highlighted this as a critical milestone in their regulatory pathway.

Autonomix's first-in-class technology platform shows potential applications across multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and pulmonary and gastrointestinal disorders.

Autonomix Medical (NASDAQ: AMIX) announced that its technology and findings from the first phase of its first-in-human proof-of-concept study will be presented at the 2025 CIRSE Annual Congress in Barcelona, Spain. The presentation, scheduled for September 15, 2025, will focus on pain mitigation in pancreatic adenocarcinoma using neurolysis via transvascular RF ablation.

The presentation will be part of SPHAIRE, CIRSE's interactive area dedicated to artificial intelligence in interventional radiology. Marco Bedoya, VP of Research and Development at Autonomix, will deliver the presentation during the "AI in IR: Machine Learning, SOP and Collaborative Development" session.

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment, has released a Virtual Investor "What This Means" segment. In this presentation, Chief Medical Officer Dr. Robert Schwartz discusses the company's recent post hoc analysis of their proof-of-concept human clinical trial (PoC 1).

The analysis revealed significant outcomes including sustained pain reduction, improved quality of life, and 100% zero opioid use among trial participants. The company's focus remains on advancing innovative technologies in neurological disease management.

Autonomix Medical (NASDAQ: AMIX) has reported promising longer-term post hoc analysis results from its PoC 1 study evaluating nerve ablation technology for pancreatic cancer pain treatment. The study demonstrated significant pain reduction of 65.6% (mean 5.08 reduction on VAS pain scale) in responding patients.

Key highlights include 100% opioid-free status among responders at 3-month follow-up, and substantial improvements in quality of life metrics: 76.5% improvement in global health, 51.5% improvement in functional ability, and 50.4% improvement in symptom management. Following these positive results, Autonomix has initiated PoC 2 phase to expand into additional visceral cancers, potentially doubling their addressable market.

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO Brad Hauser will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. Management will also conduct one-on-one meetings with qualified investors. The presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website.

Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,697,298 for its medical device technology focused on capturing and processing physiological signals. The patent strengthens the company's intellectual property portfolio, which now includes 80 issued patents and 40 pending applications.

The patented technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with enhanced sensitivity. The system includes distributed signal acquisition modules for neural mapping procedures, with capabilities spanning coronary artery/vagal nerve mapping, renal mapping, and various other applications in robotic prosthetics and neurotherapy.

Autonomix Medical (NASDAQ:AMIX), a medical device company specializing in precision nerve-targeted treatments, has announced its participation in an upcoming virtual investor webinar. The event will be hosted by Ladenburg Thalmann on Thursday, August 21, 2025, at 1:00 PM ET.

The webinar will feature Brad Hauser, President and CEO of Autonomix, in a discussion moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research at Ladenburg Thalmann. The event will include a Q&A session, with participants able to pre-submit questions via email.